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ABSTRACT: THE ROLE OF ZYXIN AND LIMD1 IN MITOSIS AND CANCER 
 
Jiuli Zhou, Ph.D. 
University of Nebraska, 2019 
Supervisor: Jixin Dong, Ph.D. 
The Hippo signaling pathway, originally discovered in Drosophila, consists of a core 
kinase cascade and has been subsequently demonstrated to control tissue growth and 
tumorigenesis. The core of this pathway contains MST1/2 (Mammalian sterile 20-like 
kinase 1/2), LATS1/2 (large tumor suppressor 1/2) and downstream effector named Yes-
associated protein (YAP) and PDZ-binding motif (TAZ). MST1/2 transduce their kinase 
activity mainly through directly phosphorylating LATS1/2. Once phosphorylated and 
activated, LATS1/2 subsequently phosphorylate and inhibit YAP/TAZ from translocating 
to nucleus, thereby suppressing the expression of downstream pro-growth and survival 
genes. While recent studies provide important insight into the tumor suppressor properties 
of this pathway, the underlying molecular mechanisms through which the Hippo 
components exert their oncogenic/suppressing function are poorly understood. Zyxin and 
LIM domains containing 1 (LIMD1) are adaptor/scaffold proteins with three LIM domains, 
which are involved in protein-protein interactions during cellular signaling transduction. 
Several recent studies showed that Zyxin/LIMD1 affect Hippo-YAP signaling. Our studies 
found that Zyxin and LIMD1 are phosphorylated in mitosis via novel sites. We further 
characterized the phospho-regulation of Zyxin and LIMD1 in mitosis and examined the 
functional significance of the phosphorylation in colon cancer and lung cancer, 
respectively. Moreover, we demonstrated that Zyxin regulates YAP activity through colon 
cancer oncogene Cyclin-Dependent Kinase 8 (CDK8). Mechanistically, we identified that 
iv 
CDK8 directly phosphorylates YAP and promotes its activation. Together, our findings 
revealed novel layers of regulation for Zyxin/LIMD1 in mitosis and their roles in 
tumorigenesis.  
v 
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CHAPTER 1: ZYXIN PROMOTES COLON CANCER TUMORIGENESIS IN 
A MITOTIC PHOSPHORYLATION-DEPENDENT MANNER AND 
THROUGH CDK8-MEDIATED YAP ACTIVATION* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*The material presented in this chapter was previously published: Zhou et al.  Proc Natl Acad Sci 
U S A. 2018 Jul 17; 115(29): E6760-E6769. 
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Abstract 
Zyxin is a member of the focal adhesion complex and plays a critical role in actin 
filament polymerization and cell motility. Several recent studies showed that Zyxin is a 
positive regulator of Yki/YAP (Yes-associated protein) signaling. However, little is known 
about the mechanisms by which Zyxin itself is regulated and how Zyxin affects Hippo–
YAP activity. We first showed that Zyxin is phosphorylated by CDK1 during mitosis. 
Depletion of Zyxin resulted in significantly impaired colon cancer cell proliferation, 
migration, anchorage-independent growth, and tumor formation in xenograft animal 
models. Mitotic phosphorylation is required for Zyxin activity in promoting growth. Zyxin 
regulates YAP activity through the colon cancer oncogene CDK8. CDK8 knockout 
phenocopied Zyxin knockdown in colon cancer cells, while ectopic expression of CDK8 
substantially restored the tumorigenic defects of Zyxin-depletion cells. Mechanistically, we 
showed that CDK8 directly phosphorylated YAP and promoted its activation. Fully 
activated YAP is required to support the growth in CDK8-knockout colon cancer cells in 
vitro and in vivo. Together, these observations suggest that Zyxin promotes colon cancer 
tumorigenesis in a mitotic-phosphorylation-dependent manner and through CDK8-
mediated YAP activation. 
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1.1. Introduction 
Zyxin is a LIM domain protein concentrated at sites of cell–cell adhesion, where it is 
proposed to dock proteins involved in cytoskeletal dynamics and signaling [1]. Zyxin has 
also been implicated in sensing the mechanotransduction signal [2, 3]. Of interest, Zyxin 
contains a nuclear export signal and shuttles between the nucleus and sites of cell 
adhesion [4], although the underlying mechanisms and function of its localization 
dynamics are unclear. Several recent studies showed that Zyxin is a positive regulator of 
tissue growth through Hippo–Yorkie/Yki signaling in Drosophila [5-8]. Zyxin regulates Yki-
mediated tissue growth by promoting F-actin polymerization independent of Hippo/Warts 
kinases [5]. This mechanism is conserved in mammalian cancer cells [9, 10]. Furthermore, 
in human breast cancer cells, Zyxin promotes growth and tumorigenesis by modulating 
Hippo–yes-associated protein (YAP) signaling activity [11], which plays an important role 
in the development and progression of many human malignancies [12-15]. Despite the 
growth-promoting role of Zyxin, however, little is known about the mechanisms by which 
Zyxin itself is regulated and how Zyxin affects Hippo–YAP (and/or other signaling) activity 
in cancer cells.  
The protein kinase cyclin-dependent kinase 8 (CDK8) is a component of the mediator 
complex that functions as a bridge between basal transcription machinery and gene-
specific transcriptional factors [16]. CDK8 is amplified and overexpressed in colon cancer 
and exerts its oncogenic activity partially through regulating β-catenin activity [17]. The 
precise mechanisms by which CDK8 regulates β-catenin remain obscure. CDK8 mRNA 
is up-regulated in malignant melanoma by loss of a transcriptional repressor called the 
histone variant macroH2A, which functions as a tumor suppressor in melanoma [18]. In 
addition, CDK8 protein levels are also controlled by S-phase kinase associated protein 2 
(Skp2)-mediated degradation of macroH2A1 protein, and these three proteins work 
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together to regulate G2/M transition and tumorigenesis in breast cancer [19]. CDK8 exerts 
its oncogenic function mainly through phosphorylation of substrates. Several substrates 
for CDK8 have been identified, including the Notch intracellular domain, SMAD 
complexes, E2F1, STAT1, and the C-terminal domain of RNA polymerase II [16]. These 
studies highlight an important oncogenic function of CDK8 kinase activity.  
A connection between CDK8 and YAP, the critical transcriptional coactivator of Hippo 
signaling, has not been established. Here, we report that Zyxin promotes colon cancer cell 
growth, and its oncogenic activity is partially controlled by mitotic phosphorylation. We 
further showed that Zyxin regulates YAP activity through CDK8 in colon cancer cells. In 
addition, we identified YAP as a direct substrate of CDK8 and CDK8-mediated 
phosphorylation that promotes YAP activity in vitro and in vivo. 
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1.2. Materials and Methods 
1.2.1.  Expression constructs  
pcDNA-YAP (no tag) expression constructs have been described  [20]. Retroviral wild 
type YAP and YAP mutant constructs have been described [21]. The human Zyxin cDNA 
clone (RFP-Zyxin) was obtained from Dr. Anna Huttenlocher’s lab (Addgene, plasmid 
#26720). To make the shRNA-resistant (sh-Res) Zyxin cDNA, the target sequence (5’-
agaaggtgagcagtattgatt-3’) was changed into 5’-agaaagtcagtagcattgatt-3’ by PCR 
mutagenesis. The mutated Zyxin cDNA was then cloned into the MaRXTM IV vector. The 
β-catenin-S33Y cDNA was a gift from Shinya Yamanaka (Addgene, plasmid #13371). The 
CDK8 cDNAs were also purchased from Addgene (#19578 and #19579). β-catenin-S33Y, 
wild type CDK8 and its kinase dead (D173A) mutant (CDK8-KD) were then subcloned into 
lentivirus-based pLVX-EF1α-IRES-mCherry vector (Clontech), which was inserted with an 
N-terminal Flag-tag with multiple-cloning-site sequences. All plasmids were confirmed by 
DNA sequencing. Point mutations were generated by the QuikChange Site-Directed PCR 
mutagenesis kit (Stratagene) and verified by sequencing.  
1.2.2. Cell culture and transfection 
HEK293T, HeLa, RKO, SW480, and DLD-1 cell lines were purchased from American 
Type Culture Collection (ATCC). The cell lines were authenticated at ATCC and were used 
at low (<25) passages. HCT116 cell line was a gift from Dr. Michael Brattain (University of 
Nebraska Medical Center), who originally established and deposited this cell line to ATCC. 
RKO cells were cultured in MEM, DLD-1 cells were maintained in RPMI-1640, and 
HCT116 cells were maintained in McCoy’s 5A media. Other cell lines were maintained in 
DMEM media and all cell lines were supplemented with 10% FBS and 1% 
penicillin/streptomycin. Attractene and HiPerFect (Qiagen) were used for transient 
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overexpression and siRNA transfections, respectively, following the manufacturer’s 
instructions. Nocodazole (100 ng/ml for 16-20 h) and taxol (0.1 µM for 16 h) were used to 
arrest cells in G2/M phase unless otherwise indicated. Zyxin siRNAs and CDK8 siRNAs 
were purchased from GenePharma and Sigma-Aldrich, respectively. All other chemicals 
were either from Sigma or Thermo Fisher.  
1.2.3. Cell cycle synchronization 
A double thymidine block and release approach was used to synchronize cells as 
described previously [22].  
1.2.4. Establishment of cell lines 
Ectopic expression of empty vector, YAP-S127A in DLD-1 (CDK8-KO) and SW480 
(CDK8-KO) cell lines was achieved by a retrovirus-mediated approach as described 
previously [23]. The transduced cells were then selected with 800 μg/ml of neomycin (at 
48 hours post-infection) to establish cell lines stably expressing exogenous proteins. Zyxin 
downregulation in HCT116, RKO, and SW480 cells was obtained by lentivirus-mediated 
Zyxin shRNA expression [24]. Ectopic expression of β-catenin-S33Y, CDK8, or CDK8-KD 
was also achieved by a lentivirus-mediated approach [24].    
1.2.5. CRISPR-double nikase-mediated knockout 
To construct the all-in-one CRISPR/Cas9 (double nickase) plasmid targeting β-
catenin, the sense and anti-sense oligonucleotides were synthesized, annealed, and 
Golden Gate assembled into the pX330A_D10A-1x2-EGFP [25] and pX330S-2 vectors as 
described previously [26]. After the two vectors were generated, a final Golden Gate 
assembly was performed to generate the all-in-one vector as described previously [26]. 
The resulting pX330A_D10A-1x2-EGFP-β-catenin-1 or -2 construct was transfected into 
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cells and GFP-positive clones were selected by flow cytometry-based cell sorting. CDK8 
and YAP CRISPR/double nickase knockout plasmids were purchased from Santa Cruz 
Biotechnology and transfection and clone selection were done as instructed by the 
manufacturer. 
1.2.6. Kinase inhibitors 
VX680 (Aurora-A, -B, -C inhibitor), ZM447439 (Aurora-B, -C inhibitor), and BI2536 
(Plk1 inhibitor) were from Selleck Chemicals. U0126 (MEK-ERK inhibitor), SB203580 (p38 
inhibitor), LY294002 (PI-3K inhibitor), rapamycin (mTOR inhibitor), and SP600125 (JNK 
inhibitor) were from LC Laboratories. RO-3306 (CDK1 inhibitor) and roscovitine (CDKs 
inhibitor) were from ENZO Life Sciences. MK5108 (Aurora-A inhibitor) was from Merck. 
SB216763 (GSK3β inhibitor) was from Sigma. 
1.2.7. Recombinant protein purification and in vitro kinase assay 
The GST-tagged full-length Zyxin proteins were purchased from Abnova. The GST-
tagged and His-tagged YAP proteins (pET-21c vector, Novagen/EMD Chemicals) were 
bacterially expressed and purified on GSTrap FF affinity columns (GE Healthcare) and 
HisPurTM Cobalt spin columns (Pierce), respectively following the manufacturer’s 
instructions [21]. 100 ng of GST-Zyxin was incubated with 10 U recombinant CDK1/cyclin 
B complex (New England Biolabs) or 100 ng other kinases (SignalChem) in kinase buffer 
[27] in the presence of 5 µCi γ-32P-ATP (3000 Ci/mmol, PerkinElmer). The reaction was 
performed at 37 oC for 30 min. CDK2, CDK5, CDK8, MEK1, ERK1, p38α, JNK1, and JNK2 
active kinases were purchased from SignalChem. The samples were resolved by SDS-
PAGE, transferred onto PVDF (Millipore) and visualized by autoradiography followed by 
Western blotting. 
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1.2.8. Antibodies 
Rabbit polyclonal phospho-specific antibodies against Zyxin S281, S308, and S344 
were generated and purified by AbMart, Inc. The peptides used for immunizing rabbits 
were VASKF-pS-PGAPG (S281), SAGTG-pS-PQPPS (S308), and QNQVR-pS-PGAPG 
(S344). The corresponding non-phosphorylated peptides were also synthesized and used 
for antibody purification and blocking assays. Anti-Zyxin, p-YAP S127, YAP, p-β-catenin 
S33/S37/T41, p-Cofilin S3, Cofilin, p-H3 S10, Survivin, and p-Aurora-A/B/C were from Cell 
Signaling Technology. Anti-GST, His, and CDK8 antibodies were from Bethyl Laboratory. 
Anti-Aurora-A, β-tubulin, and Flag antibodies were from Sigma. Anti-Cyclin B1, β-actin, 
and β-catenin were purchased from Santa Cruz Biotechnology. 
1.2.9. Phos-tag and Western blot analysis 
Phos-tagTM was obtained from Wako Pure Chemical Industries, Ltd. (304-93521) and 
used at 20 µM (with 100 µM MnCl2) in 8% SDS-acrylamide gels. Prior to transferring, the 
gels were equilibrated in transfer buffer containing 10 mM EDTA for two times, each 10 
min. The gels were then soaked in transfer buffer (without EDTA) for another 10 min. 
Western blotting and lambda phosphatase treatment assays were done as previously 
described [27].  
1.2.10. Immunofluorescence staining and confocal microscopy 
Cell fixation, permeabilization, fluorescence staining, and microscopy were done as 
previously described [28]. The stained cells were mounted with Fluoromount (Vector 
Laboratories) and visualized on an LSM710 Zeiss fluorescence microscope (Carl Zeiss). 
The Slidebook 4.2 software (Intelligent Imaging Innovations) was used for analyzing and 
processing all immunofluorescence images. F-actin was stained using rhodamine-labeled 
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phalloidin (Cytoskeleton). YAP cellular localization was visualized by YAP 
immunofluorescence staining with an Alexa Fluor 647-conjugated YAP antibody (Cell 
Signaling Technology). For peptide blocking, the phospho-Zyxin antibodies were first 
neutralized by an excess of immunizing (phosphorylated) peptides (1 µg/ml for 1 h at room 
temperature). The antibody (containing the phospho-peptide) was then used for staining 
in parallel with staining using antibodies with no peptide or non-phospho-peptide.  
1.2.11. Cell proliferation, cell migration (wound healing) and colony formation 
assays 
Colony formation assays in soft agar were performed as described [20]. Cells 
(5,000/well) were seeded in 6-well plates and colonies were counted by ImageJ online. 
For cell proliferation assays, cells (SW480 and HCT116: 100,000/well; RKO and DLD-1: 
50,000/well) were seeded in a 6-well plate in triplicate. Cells were counted by the 
automated cell counter (Invitrogen) at indicated time points and proliferation curves were 
made based on the cell number in each well from at least three independent experiments. 
For wound healing (migration) assays, the cell monolayer was scratched by a P200 pipet 
tip when cells were confluent. Cells were washed three times with PBS, and were 
incubated with 2 ml of serum-free medium for an additional 24 h. The wound width was 
measured by QCapture Software (QImaging). 
1.2.12. Quantitative real time PCR 
Total RNA isolation, RNA reverse transcription and quantitative real time-PCR were 
done as we have described previously [23].  
1.2.13. Animal studies 
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For in vivo xenograft studies, RKO cells (shControl, shZyxin, shZyxin with Res-Zyxin-
WT or Res-Zyxin-3A) (1.0x106 cells each injection, mixed with Matrigel at 1:1 ratio) were 
subcutaneously injected into the left or right flank of 6-week-old male athymic nude mice 
(Nude-Foxn1nu, Envigo). Five animals (10 injections) were used per group. Similar 
approaches were used for DLD-1 (1.0x106 cells/injection) and SW480 (2.5x106 
cells/injection) cells. Tumor sizes were measured at the indicated time points. Tumor 
volume (V) was calculated by the formula: V= 0.5 x length x width2 [20]. Mice were 
euthanized at the end of the experiments and the tumors were excised for subsequent 
analysis. The animals were housed in pathogen-free facilities. All animal experiments 
were approved by the University of Nebraska Medical Center Institutional Animal Care 
and Use Committee. 
1.2.14. Immunohistochemistry (IHC) staining and scoring 
Tissue microarray slides (TMA) were obtained from the tissue bank at the University 
of Nebraska Medical Center. The TMAs consist of 31 normal and 74 cancer cases. Slide 
deparaffinization, antigen retrieving, and blocking were performed as we have described 
[20]. Tumors from RKO xenografts (control and Zyxin knockdown) were also used for 
Zyxin antibody validation. The sections were then stained with anti-Zyxin antibody (Cell 
Signaling Technology, at 1:100 dilutions) using a Histostain-Plus IHC kit following the 
manufacturer’s instructions (Invitrogen). The TMAs were also stained with anti-CDK8 
antibody (Bethyl Laboratory, IHC-00704, at 1:300 dilutions). Cell nuclei were stained with 
hematoxylin. Ventana iScan HT (Roche) was used for slide scanning with a 20X objective 
lens. The staining results were independently evaluated by three researchers including 
one pathologist (S.M.L.). The staining intensity (a scale of 0 to 3 was used: 0-negative, 1-
weak, 2-moderate, and 3-strong) were scored. 
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1.2.15. Statistical analysis 
Statistical significance was evaluated using a two-tailed, unpaired Student’s t-test. The 
Wilcoxon rank sum test was used to compare the IHC staining data between groups. A P 
value of <0.05 was considered as indicating statistical significance. 
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1.3. Results 
1.3.1. Zyxin is phosphorylated by CDK1 in vitro during mitosis 
Others and we have shown that several Hippo–YAP components are regulated and 
implicated in mitosis [21, 24, 27, 29-32]. These studies suggest that the Hippo–YAP 
pathway controls tumorigenesis through dysregulation during mitosis. Given the 
connection between Zyxin and Hippo–YAP signaling, we tested the possibility that Zyxin 
might contribute to tumorigenesis through regulating cell cycle progression, especially 
mitosis. As shown in Fig. 1-1A, treatment with taxol or nocodazole — both agents that 
bind to microtubules and arrest cells in mitosis significantly increased mobility upshift of 
Zyxin on a Phos-tag gel (Fig. 1-1A). Lambda phosphatase treatment completely converted 
all slow-migrating bands to fast-migrating bands, confirming that Zyxin is phosphorylated 
in mitosis induced by spindle poisons (Fig. 1-1B). Next, we used various kinase inhibitors 
to identify the candidate kinase for Zyxin phosphorylation. Of interest, treatments with 
RO3306 (CDK1 inhibitor) or Purvalanol A (CDK1/2/5 inhibitor) significantly inhibited 
mobility shift and phosphorylation (Fig. 1-1C, lanes 5 and 6). These data suggest that 
CDK1, a well-known master mitotic kinase, is likely the relevant kinase for Zyxin 
phosphorylation. Fig. 1-1D shows that purified CDK1/cyclin B kinase complex (CDK2 and 
CDK5/p25 kinases to a lesser extent) directly phosphorylated GST–Zyxin proteins in vitro 
(Fig. 1-1D). Zyxin is not a suitable substrate for MAPK-p38α, MEK1, ERK1, and JNK1/2 
kinases in vitro (Fig. 1-1D), although these kinases recognize the same phosphorylation 
sequence consensus as CDK1. 
1.3.2. Zyxin is phosphorylated by CDK1 in cells during mitosis 
CDK1 phosphorylates an S/TP consensus sequence [33]. Database analysis identified 
three SPs (S281, S308, and S344) as possible main phosphorylation sites in Zyxin during 
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mitosis [34]. We generated phospho-specific antibodies against these sites. Nocodazole 
or taxol treatment significantly increased phosphorylation of S281, S308, and S344 of 
endogenous Zyxin (Fig. 1-1E). Phosphopeptide, but not regular nonphosphopeptide, 
incubation completely blocked the phospho-signal, suggesting that this antibody detects 
the phosphorylated form of Zyxin (Fig. 1-2A–C). Exogenous Zyxin was also 
phosphorylated during mitotic arrest, and mutating serines to nonphosphorylatable 
alanines abolished the phosphorylation (Fig. 1-2D). The siRNA-mediated depletion of 
Zyxin significantly blocked the phospho-signal, confirming the specificity of these 
phosphor-antibodies (Fig. 1-1F). Phosphorylation of Zyxin occurred in dose-dependent 
and time course-dependent manners (Fig. 1-2E and F). Using kinase inhibitors, we 
demonstrated that phosphorylation of Zyxin is CDK1 kinase-dependent (Fig. 1-1G, lanes 
5 and 6). Furthermore, knockdown of Cyclin B1 or CDK1 largely blocked Zyxin 
phosphorylation (Fig. 1-1H and Fig. 1-2G). Enhanced expression of active CDK1/ Cyclin 
B1 was sufficient to stimulate Zyxin phosphorylation (Fig. 1-2H).  
Immunofluorescence staining revealed that a strong signal was detected in 
nocodazole-arrested prometaphase cells for antibodies against Zyxin S281 and S344 
(Fig. 1-3A and B, Upper, white arrows). Very low or no signal was detected in interphase 
cells (Fig. 1-3Aand B, yellow arrows). Again, phosphopeptide, but not 
nonphosphopeptide, incubation completely blocked the signal, suggesting that these 
antibodies specifically detect phosphorylated Zyxin (Fig. 1-3A and B). The specificity of 
the antibodies was further confirmed by siRNA knockdown of Zyxin (Fig. 1-3C and D). 
Addition of RO3306 largely abolished the signals detected by p-Zxyin S281 and S344 
antibodies in mitotic cells, further indicating that the phosphorylation is CDK1-dependent 
(Fig. 1-3A and B, Lower). 
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 To determine whether mitotic phosphorylation of Zyxin occurs during 
unperturbed/normal mitosis, we performed immunofluorescence staining on cells 
collected from a double thymidine block and release [28]. Very weak signals were detected 
in interphase or telophase/cytokinesis cells (Fig. 1-4A and B, yellow arrows, and Fig. 1-
5A and B). The phospho-signal increased in prometaphase and peaked in metaphase 
cells (Fig. 1-4A and B, white arrows, and Fig. 1-5A and B). After being released from 
double thymidine block, cells entered into mitosis at 10–12 h [21, 30] (revealed by 
increased p-S10 H3 levels), and p-Zyxin S281 and S344 signals also increased in these 
cells (Fig. 1-4C). Mitotic phosphorylation of Zyxin occurred in freely cycling cells in a 
CDK1-dependent manner (Fig. 1-6A and B). These observations indicate that Zyxin is 
phosphorylated by CDK1 during mitosis. 
1.3.3. Zyxin expression is induced during mitosis 
During our experiments, we noticed that, in addition to mobility shift/phosphorylation, 
Zyxin protein levels were also increased during taxol or nocodazole-induced mitotic arrest 
(Fig. 1-4D) and in normal mitosis (Fig. 1-6D). Quantitative RT-PCR (qRT-PCR) confirmed 
that Zyxin mRNA levels were induced by taxol or nocodazole (Fig. 1-4E) and in normal 
mitosis (Fig. 1-4F). YAP targets survivin and Cyr61, but not YAP itself, were induced in 
mitosis (Fig. 1-4F and Fig. 1-6C–E). A previous study showed that Zyxin is a direct target 
of TAZ (a paralog of YAP)/ TEAD [35] , and we determined whether Zyxin induction in 
mitosis is YAP/TAZ-dependent. Indeed, addition of verteporfin [(VP) a YAP/TEAD inhibitor 
[36] ] or knockdown of YAP largely abolished Zyxin mRNA increase induced by taxol or 
nocodazole treatment (Fig. 1-4G and Fig. 1-6F). Of interest, inhibition of CDK1 by 
Purvalanol A also blocked Zyxin expression, suggesting that Zyxin expression in mitosis 
is induced in a CDK1-dependent manner (Fig. 1-4G). 
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1.3.4. Zyxin is required for colon cancer cell growth in vitro and in vivo 
We next explored the biological significance of Zyxin in cancer cell growth. We 
analyzed the Oncomine and TCGA online databases and found Zyxin to be highly 
expressed in colon cancer (Fig. 1-7A). We performed immunohistochemistry (IHC) 
staining on tissue microarrays (TMAs) (n = 66 cancer/tumor, n = 35 normal) and confirmed 
that Zyxin protein levels were significantly increased in colon cancer samples compared 
with normal tissue (Fig. 1-7B and C). The specificity of the Zyxin IHC was validated by 
using Zyxin knockdown tumor samples (Fig. 1-7D). These findings highlight a critical role 
of Zyxin in tumorigenesis in colon cancer. 
To directly determine the role of Zyxin in colon cancer, we depleted Zyxin (with two 
independent shRNAs) in various colon cancer cells (Fig. 1-7E–G). Knockdown of Zyxin 
greatly reduced migration (as shown by the wound healing assay) (Fig. 1-7H–J and Fig. 
1-8A–C), anchorage-independent growth (Fig. 1-7K and L and Fig. 1-8D and E), and 
proliferation (Fig. 1-7M–O) in RKO, SW480, and HCT116 cells. Importantly, reexpression 
of shRNA-resistant wild-type Zyxin completely rescued all these phenotypes in RKO cells 
(Fig. 1-9A–C). However, expression of nonphosphorylatable mutant Zyxin-3A 
(S281A/S308A/S344A) only partially restored these characteristics (Fig. 1-9B and C), 
suggesting that mitotic phosphorylation is required for Zyxin oncogenic activity in colon 
cancer cells. Similar results were observed in SW480 cells (Fig. 1-9D–F). As expected, 
Zyxin knockdown also greatly reduced tumor growth in animals, and cells bearing Zyxin-
3A formed much smaller tumors compared with cells expressing wild-type Zyxin (Fig. 1-
9G and H). Knockdown efficiency was confirmed, and reexpression levels between wild-
type and mutant Zyxin (Zyxin-3A) were similar in tumors (Fig. 1-8F). These results suggest 
a critical role of Zyxin and its mitotic phosphorylation in colon cancer. 
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1.3.5. Zyxin regulates YAP activity in colon cancer cells 
Zyxin has been shown to be a positive regulator of YAP/Yki activity [5-8, 11]. We 
confirmed that Zyxin knockdown increased p-YAP S127 levels and promoted YAP 
cytoplasmic localization (Fig. 1-10A and B). Consistent with reduced YAP activity, 
expression of the target gene CTGF was significantly reduced upon Zyxin knockdown in 
both RKO and SW480 cells (Fig. 1-10C). F-actin cytoskeletal remodeling was shown to 
control YAP/Yki activity in mammalian cells and in Drosophila [5-9, 37-39]. F-actin 
polymerization was inhibited by cofilin, for which activity is negatively controlled by 
phosphorylation at Serine3 [40-42]. We found that phospho-S3 cofilin levels were reduced 
and F-actin formation/cytoskeleton was strongly inhibited upon Zyxin knockdown in colon 
cancer cells (Fig. 1-10D and E), suggesting that Zyxin might control YAP activity and 
subsequent cell migration and proliferation through F-actin remodeling.  
To explore the functional interaction between Zyxin and YAP, we reexpressed YAP–
S127A in Zyxin knockdown cells (Fig. 1-10F and G). Enhanced expression of YAP–S127A 
completely rescued the effects (migration and proliferation) of Zyxin knockdown in both 
SW480 and HCT116 cells (Fig. 1-10H–K), suggesting that Zyxin promotes colon cancer 
cell growth through YAP. 
1.3.6. Zyxin regulates CDK8 to promote migration and proliferation in colon 
cancer cells 
To elucidate the underlying mechanisms in which Zyxin regulates YAP activity and 
controls colon cancer cell growth, we performed an array analysis involving 84 cell cycle 
regulators in control and Zyxin-knockdown cells. Five genes were down-regulated and 
one gene up-regulated (CDKN2B) in Zyxin-depleted cells compared with control cells (Fig. 
1-11A). Most (except for NBN) were confirmed by qRT-PCR in an independent Zyxin-
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knockdown cell line (Fig. 1-12A). Among these genes, CDK8 (cyclin-dependent kinase 8) 
attracted us, since it functions as an oncogene in colon cancer [17] and in melanoma [18]. 
We confirmed that CDK8 protein levels were also reduced in Zyxin-knockdown RKO and 
SW480 cells (Fig. 1-11B) and restored by reexpression of exogenous Zyxin (Fig. 1-12B). 
The Zyxin-3A mutant had similar activity to wild-type Zyxin in rescuing CDK8 levels, 
suggesting that mitotic phosphorylation of Zyxin is dispensable in controlling CDK8 
expression (Fig. 1-12B). Importantly, ectopic expression of CDK8, but not the kinasedead 
form (CDK8-KD), substantially restored the migratory (assayed by wound healing) and 
proliferating ability of Zyxin depleted RKO and SW480 cells (Fig. 1-11C–F). Moreover, 
siRNA-mediated transient knockdown (two independent siRNAs) or CRISPR/double 
nickase-mediated knockout (KO; two independent gRNAs) [25] of CDK8 significantly 
impaired cell migration, proliferation, and anchorage-independent growth in SW480 cells 
(Fig. 1-11G–L). CDK8 KO also reduced proliferation in DLD-1 cells (Fig. 1-11M and N). Of 
note, both mRNA and protein levels of CDK8 were up-regulated in colon tumors compared 
with normal tissue (Fig. 1-12C and D). We found that CDK8 and Zyxin protein levels were 
positively correlated in metastatic colon cancer samples (Fig. 1-12E and F). Together, 
these data suggest that Zyxin promotes colon cancer cell growth via CDK8.  
In line with the above functional studies, reexpression of CDK8 largely restored the 
YAP phosphorylation and target gene (CTGF) expression in Zyxin knockdown cells (Fig. 
1-13A and B), suggesting that Zyxin regulates YAP activity through CDK8. 
1.3.7. CDK8 requires YAP to promote cell growth in colon cancer 
Based on our observations that Zyxin regulates YAP through CDK8 (Figs. 1-11, 1-13A 
and B), we reasoned that CDK8 also controls YAP activity. Indeed, we found that S127 
phosphorylation of YAP was increased in CDK8-KO cells (Fig. 1-13C). Consistent with 
18 
decreased activity of YAP in CDK8-KO cells, the expression of YAP target gene CTGF 
was inhibited upon CDK8 deletion (Fig. 1-13D). Furthermore, CRISPR-mediated KO (two 
independent gRNAs) of YAP strongly inhibited migration and proliferation in RKO and 
SW480 cells in which Zyxin was depleted and CDK8 reexpressed (Fig. 1-13E–H), 
suggesting that YAP is essential for CDK8-driven tumorigenesis in colon cancer. Thus, 
we identified CDK8 as a positive regulator of YAP activity. 
1.3.8. CDK8 phosphorylates and promotes YAP activity 
  CDK8 is a member of the mediator complex, which couples transcriptional regulators 
to control basal transcription [16]. Since CDK8 is a kinase and regulates YAP 
transcriptional activity, we tested whether CDK8 directly phosphorylates YAP. In vitro 
kinase assays showed that purified CDK8/Cyclin C complex readily phosphorylated GST- 
or His-tagged YAP proteins (Fig. 1-13I and J). CDK8 could also undergo 
autophosphorylation under these conditions (Fig. 1-14). CDKs phosphorylate at S/T-P 
minimal consensus sequences. YAP contains seven conserved S/TPs (T119, S128, S138, 
S217, S289, S367, and T412; the T143, T154, and S340 sites do not exist in mouse and 
were excluded from further analysis). Of interest, mutating four amino acid positions 
(T119, S128, S289, and S367) to alanines (YAP-4A) completely blocked phosphorylation 
(Fig. 1-13J), suggesting that CDK8 phosphorylates these sites in YAP in vitro.  
Given that both Zyxin (Figs. 1-1 and 1-2) and YAP are phosphorylated during mitosis 
[21, 43], we next explored whether CDK8 phosphorylates YAP in mitosis. Interestingly, 
S128 phosphorylation was significantly increased in nocodazole-arrested mitotic cells 
(Fig. 1-13K). Consistent with our previous study [21], phosphorylation of T119 and S289 
was also increased in mitotic cells (Fig. 1-13K). Importantly, CDK8 deletion largely blocked 
the phosphorylation of all three sites induced by mitotic arrest, suggesting that CDK8 is a 
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relevant YAP kinase in vivo, specifically in mitosis (Fig. 1-13K). Using reporter assays, we 
next examined whether phosphorylation of YAP affects its activity. Mutating these four 
sites to alanines greatly suppressed YAP–S127A activity (Fig. 1-13L). These observations 
suggest that CDK8 directly phosphorylates and promotes YAP transcriptional activity, 
identifying YAP as a direct substrate for CDK8. 
1.3.9. YAP phosphorylation is required for CDK8-driven migration and proliferation 
  To further explore the functional relationship between CDK8 and YAP, we performed 
complementary experiments. Ectopic expression of the constitutively active form of YAP 
(YAP–S127A) had little impact on proliferation and migration in SW480 and DLD-1 CDK8-
KO cells (Fig. 1-15A and B). Expression of phospho-mimetic mutant YAP-4D failed to 
rescue proliferation and migration in CDK8-KO cells (Fig. 1-16A and B). However, 
expression of YAP-S127A/4D (highest activity) substantially (but not completely) restored 
CDK8-KO–mediated migration, proliferation, and anchorage-independent growth, 
suggesting that CDK8-mediated phosphorylation is essential for full activation of YAP (Fig. 
1-16B–E and Fig. 1-15C–E), which is consistent with our earlier observations (Fig. 1-13). 
CDK8 KO significantly inhibited tumor growth in vivo in both SW480 and DLD-1 cells (Fig. 
1-16F–I). Ectopic expression of YAP–S127A/4D also largely restored tumor growth of 
CDK8-KO cells in animals (Fig. 1-16F–I). 
 A previous report showed that CDK8 functions as a colon oncogene through 
regulating β-catenin [17]. Consistent with this study, the inhibitory phosphorylation of β-
catenin was increased, and target gene (LEF1) expression was inhibited in CDK8-KO cells 
(Fig. 1-17A and B). Interestingly, KO of β-catenin also greatly impaired migration and 
proliferation in RKO cells with Zyxin depletion and CDK8 reexpression (Fig. 1-17C–E). 
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These findings suggest that CDK8 controls YAP and β-catenin activity, both of which are 
critical regulators in colon cancer.  
Like YAP–S127A or YAP-4D, enhanced expression of β-catenin–S33Y (active form) 
had little effect on CDK8-KO cell growth (Fig. 1-16B and Fig. 1-15A, B, and D), suggesting 
that active β-catenin alone is not sufficient to rescue CDK8-KO–mediated cell growth. 
Coexpression of β-catenin-S33Y with YAP–S127A/4D did not further increase growth 
compared with YAP–S127A/4D alone in CDK8-KO cells (Fig. 1-16B–I, Fig. 1-15D and E). 
Our data suggest that CDK8 promotes YAP activation through a twofold mechanism: 
canonical S127 phosphorylation and direct phosphorylation. Both YAP and β-catenin are 
required for CDK8-driven tumorigenesis in colon cancer. Altogether, our findings indicate 
that Zyxin promotes colon tumorigenesis in a mitotic phosphorylation-dependent manner 
and through CDK8-mediated YAP activation. 
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1.4. Discussion 
Our study revealed that the cell-adhesion protein Zyxin promotes colon cancer cell 
growth by controlling CDK8 expression. It is currently not known how Zyxin regulates 
CDK8 expression. CDK8 mRNA expression is negatively regulated by the histone variant 
macroH2A [18]. A recent study demonstrated that the E3 ligase, Skp2, promotes 
macroH2A ubiquitination and degradation [19]. Interestingly, in our array analysis, Skp2 
is one of the five genes down-regulated by Zyxin depletion (Fig. 1-11 and Fig. 1-12A). 
Therefore, it is possible that Zyxin controls CDK8 expression through the Skp2–macroH2A 
axis. Since both Zyxin and CDK8 levels are increased in colon cancer patients (Fig. 1-7 
and Fig. 1-12C and D) and possess oncogenic roles in colon cancer development [17], it 
will be interesting to explore the biological significance of Skp2 and macroH2A in colon 
cancer and their functional interactions with Zyxin/CDK8.  
CDK8 positively regulates β-catenin transcriptional activity in colon cancer cells [17], 
although the precise mechanism remains obscure. It may involve the phosphorylation of 
E2F1 and relieve E2F1-mediated repression on β-catenin/TCF signaling activity [17, 44, 
45]. The kinase activity of CDK8 is necessary for β-catenin–driven transcription [17]. 
Furthermore, a dominant-negative TCF construct, previously shown to inhibit β-catenin–
induced cellular transformation, also only partially abrogated CDK8 activity [17]. This 
notion is supported by the observations that several profiling experiments failed to identify 
the broad deregulation of β-catenin signaling in CDK8-disturbed cells [16]. These results 
strongly indicate that CDK8 controls additional factor(s) also outside the β-catenin 
signaling pathway to promote colon cancer cell growth (i.e., other factors in addition to β-
catenin exist downstream of CDK8). Although our data (Fig. 1-17D and E) and previous 
studies [17] showed that β-catenin–KO suppressed the CDK8-driven cell migration and 
proliferation, restoration of β-catenin in CDK8-KO cells was not sufficient to support colon 
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cancer cell growth (Fig. 1-15), further suggesting that β-catenin signaling is not the main 
(or only) effector of CDK8. Our study highlights the importance of YAP in mediating CDK8-
driven tumorigenesis in colon cancer (Figs. 1-13 and 1-16). CDK8 regulates YAP activity 
through a twofold mechanism: phosphorylation on S127/localization and direct 
phosphorylation at T119/S128/S289/S367 (Figs. 1-13 and 1-16). CDK8-mediated direct 
phosphorylation promotes YAP further activation and is required for CDK8-KO cell growth 
(Fig. 1-16). These observations not only added additional layers of YAP regulation, but 
also raised complex questions. For example, S128 has been shown to be phosphorylated 
by Nemo-like kinase [46, 47], and T119/S289/S367 are phosphorylated by CDK1 [21]. 
How these kinases and phosphorylation are coordinated in cells requires further 
investigation. Another question is: How does CDK8 regulate YAP S127 phosphorylation 
and localization? YAP S127 is largely mediated by Lats1/2 kinases in the Hippo pathway; 
however, we did not observe significant changes of Lats1/2 kinase activity (revealed by 
phosphorylation levels of their activation loop) in CDK8-KO cells and -intact cells, 
suggesting a Hippo-independent regulation of YAP activity.  
Our study showed that the active β-catenin mutant (β-catenin–S33Y) had little effect 
on rescuing the phenotypes of CDK8 KO in colon cancer cells (Fig. 1-15). This implies 
that additional target(s) exists or, alternatively, that β-catenin–S33Y (like YAP–S127A) is 
not fully active in CDK8-deleted cells. The similarity between YAP and β-catenin prompted 
us to reason that β-catenin is a direct substrate for CDK8. Indeed, β-catenin sequence 
analysis revealed three S/TP phospho-consensus (S191/S246/S605) as potential sites for 
CDK8 phosphorylation, and these sites have been shown to be important for β-catenin 
cellular localization and activity [48].  
The global burden of colon cancer is rising steadily. Although much progress has been 
made in therapeutic approaches, for often unresectable for cure, survival remains poor 
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[49]. Furthermore, available treatment options for colon cancer are very limited due to lack 
of validated targets. Our study has demonstrated the critical role and regulatory 
mechanisms of the Zyxin–CDK8–YAP/β-catenin signaling in colon cancer. These studies 
suggest that this axis is a potential therapeutic target and provide several options for 
targeted therapy using small-molecule inhibitors in colon cancer. For example, CDK8 
function requires its kinase activity, and several selective inhibitors have been developed 
[16, 50, 51]. Furthermore, animal studies confirmed the potential efficacy of CDK8 
inhibitors [52], although interpretation of CDK8 inhibitor data requires caution since CDK8 
may also have a tumor-suppressive function during early stages of colon tumorigenesis 
[53]. VP was recently identified as an effective compound for preventing YAP activity [36]. 
Interestingly, VP (without light activation) significantly inhibited YAP activity in vitro and 
suppressed YAP-driven tumorigenesis in the mouse liver [36]. Subsequent studies further 
confirmed that VP is also effective in inhibiting tumor growth in prostate cancer [54], uveal 
melanoma [55, 56], and colon cancer in vivo [57], suggesting that inhibiting YAP is a viable 
strategy in cancer treatment. Cyclin D1 is frequently deregulated in colon cancer and is a 
known target of β-catenin signaling [17, 58]. Interestingly, Cyclin D1 was also induced by 
YAP activation in the intestine [59] and was identified as a direct target of YAP/TEAD in 
mesothelioma cells [60]. Therefore, Cyclin D1 is a common target of YAP and β-catenin. 
Cyclin D1 is upregulated (probably through YAP/β-catenin activation) in the ApcMin/+ mice, 
and deletion of Cyclin D1 blocks/reduces ApcMin/+- driven adenoma formation [61]. Acute 
deletion of Cyclin D1 in adult mice does not affect the animal’s health [62]. These 
observations suggest that targeting Cyclin D1 (e.g., with Palbociclib/PD-0332991, which 
is a Food and Drug Administration-approved selective inhibitor of Cyclin D1–CDK4/6) 
would be a viable strategy in colon cancer, especially in CDK8 and YAP/β-catenin–
activated subtypes. 
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Figure 1-1. CDK1 phosphorylation of Zyxin during mitotic arrest 
(A) Taxol (100 nM for 16 h) or nocodazole (Noco, 100 ng/ml for 16 h) treatments in HeLa 
cells caused mobility upshift of Zyxin on Phos-tag SDS-polyacrylamide gels. (B) HeLa 
cells were treated with nocodazole (Noco) as indicated and cell lysates were further 
treated with (+) or without (-) λ phosphatase (ppase). (C) HeLa cells were treated with 
taxol together with or without various kinase inhibitors as indicated. Inhibitors were added 
(with MG132 to prevent cyclin B from degradation and cells from exiting from mitosis) 1.5 
h before harvesting the cells. (D) In vitro kinase assays with purified kinases using 
bacterially purified GST-Zyxin (Abnova) and MBP (myelin basic protein) (Sigma) proteins 
as substrates. MBP proteins were included as positive controls, confirming the kinases 
are active. (E) Zyxin is phosphorylated at multiple sites during mitotic arrest. HeLa cells 
were treated as in (A) and total cell lysates were probed with the indicated antibodies. (F) 
Validation of phospho-specific antibodies. HeLa cells were transfected with 40 nM 
scramble (control) or 40 nM siRNA against Zyxin for 48 h and were further treated with 
nocodazole as indicated. (G) HeLa cells were treated as in (C). Total cell lysates were 
subjected to Western blotting with the indicated antibodies. (H) HeLa cells were 
transfected with 40 nM scramble (control) or siRNA against Cyclin B1 for 48 h and were 
further treated with taxol as indicated. 
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Figure 1-1. CDK1 phosphorylation of Zyxin during mitotic arrest 
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Figure 1-2. Validation of phospho-specific antibodies of Zyxin 
(A-C) HeLa cells were treated with nocodazole (Noco) or taxol for 16 h. Total cell lysates 
were subjected to Western blotting with the indicated antibodies. Non-phosphopeptide: 
Western blotting in the presence of control (not phosphorylated) peptide; Phosphopeptide: 
Western blotting in the presence of corresponding phosphorylated peptide (used for 
antibody generation). Increased Cyclin B levels mark the cells in mitosis. (D) HEK293T 
cells were transfected with RFP-Zyxin mutants as indicated. At 32 h post-transfection, the 
cells were treated with nocodazole for 16 h. Total cell lysates were subjected to Western 
blotting with the indicated antibodies. Both endogenous (lower bands) and exogenous 
(RFP-tagged, upper bands) Zyxin were shown. Increased p-Aurora kinases mark the cells 
in mitosis. (E, F) Dose- and time course-dependent phosphorylation of Zyxin. HeLa 
cells were treated as indicated. Total cell lysates were subjected to Western blotting with 
the indicated antibodies. (G) CDK1 knockdown inhibited Zyxin phosphorylation. TetOn-
inducible shRNA targeting CDK1 was expressed in HeLa cells. The cells were treated with 
or without Doxycycline (Dox) for 2 days and were further treated with nocodazole (Noco) 
for an additional 16 h. Total cell lysates were subjected to Western blotting with the 
indicated antibodies. Increased p-H3 S10 levels mark the cells in mitosis. (H) HEK293T 
cells were transfected as indicated. At 48 h post-transfection, total cell lysates were 
subjected to Western blotting with the indicated antibodies. F-CDK1-AF indicates the 
constitutive active form of CDK1 (T14 and Y15 sites were mutated to non-
phosphorylatable Alaline and Phenylalanine). GFP-CycB-CA: constitutive active of Cyclin 
B1 (R42A non-degradable mutant). 
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Figure 1-2. Validation of phospho-specific antibodies of Zyxin 
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Figure 1-3. CDK1 phosphorylates Zyxin during mitotic arrest  
(A, B) HeLa cells were treated with nocodazole and then fixed. Before the cells were 
stained with phospho-specific antibody against S281 or S344 of Zyxin, they were pre-
incubated with PBS (no peptide control), or non-phosphorylated (control) peptide, or the 
phosphorylated peptide used for immunizing rabbits. CDK1 inhibitors RO3306 (5 µM) or 
Purvalanol A (10 µM) together with MG132 (25 µM) were added 2 h before the cells were 
fixed. White and yellow arrows mark some of the prometaphase cells and the interphase 
cells, respectively. (C, D) HeLa cells were transfected with scramble (Control) siRNA or 
siRNAs targeting Zyxin. At 48 h post-transfection, cells were treated with nocodazole and 
then fixed for staining with p-S281 Zyxin (C) or p-S344 Zyxin (D) antibodies. White arrows 
mark some of the metaphase cells. 
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Figure 1-3. CDK1 phosphorylates Zyxin during mitotic arrest  
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Figure 1-4. Zyxin is phosphorylated and induced during unperturbed mitosis  
(A) HeLa cells were synchronized by a double thymidine (DT) block and release method. 
Cells were stained with antibodies against p-Zyxin S281 or β-tubulin, or with DAPI. A 40X 
objective lens was used to view various phases of the cells in a field. (B) Experiments 
were done similarly as in (A) with p-Zyxin S344 antibodies.  White and yellow arrows (in 
panels A and B) mark the metaphase and interphase cells, respectively. (C) HeLa cells 
were synchronized by a DT block and release method. Total cell lysates were harvested 
at the indicated time points and subjected to Western blotting analysis. (D) Zyxin protein 
levels increased during mitotic arrest. (E) Zyxin mRNA levels were induced during mitotic 
arrest. (F) Zyxin mRNA levels were increased during normal mitosis. HeLa cells were 
treated as in (C) and harvested at 10 h post release. Survivin serves as a positive control. 
(G)HeLa cells were treated with taxol and inhibitors were added 2 h before harvesting the 
cells. Quantitative RT-PCR was performed to measure Zyxin mRNA levels.  Data were 
expressed as the mean ± s.e.m. of three independent experiments (E-G). ***: p< 0.001; 
**: p< 0.01 (t-test). 
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Figure 1-4. Zyxin is phosphorylated and induced during unperturbed mitosis  
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Figure 1-5. Zyxin is phosphorylated during unperturbed mitosis 
(A, B) HeLa cells were synchronized by a double thymidine block and release method. 
Cells were stained with antibodies against p-Zyxin S281 (A) or p-Zyxin S344 (B) or β-
tubulin, or with DAPI. Representative cells in different mitotic phases were shown. 
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Figure 1-5. Zyxin is phosphorylated during unperturbed mitosis 
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Figure 1-6. Phosphorylation of Zyxin occurs during normal mitosis 
(A, B) Immunofluorescence (IF) staining of p-Zyxin in freely cycling HeLa cells. IF staining 
procedures were described in the main text. White arrows mark cells in metaphase 
(condensed and aligned chromosomes). CDK1 inhibitors (Purvalanol A or RO3306) were 
added 1.5 h before the cells were fixed. (C) Quantitative RT-PCR revealed that YAP 
mRNA levels were not induced during mitosis. HeLa cells were synchronized by a double 
thymidine block and release method and collected at 10 h post release (G2/M). 
Asynchronized cells (G1/S) were also included. N.S.: not significant. (D) HeLa cells were 
synchronized by a double thymidine (DT) block and release method and collected at the 
indicated time points. Total cell lysates were subjected to Western blotting with the 
indicated antibodies. Increased p-H3 S10 and Cyclin B levels mark the cells in mitosis. 
Increased survivin level in mitosis serves as a positive control. (E) HeLa cells were treated 
as in D and RNAs were used for quantitative RT-PCR. Data were expressed as mean ± 
s.e.m from three independent experiments. **: p<0.01 (t-test). (F) HeLa cells were 
transfected with siRNA targeting YAP (40 nM) for 48 h and were treated nocodazole 
(Noco) for an additional 18 h.  
 
  
35 
 
Figure 1-6. Phosphorylation of Zyxin occurs during normal mitosis 
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Figure 1-7. Zyxin levels are increased in colon cancer patients and knockdown of 
Zyxin inhibits colon cancer cell growth 
(A) Zyxin mRNA levels are increased in colon cancer samples. RNA-Seq data from The 
Cancer Genome Atlas (TCGA) were downloaded from NCBI's Gene Expression Omnibus 
(GEO) with the accession number of GSE62944 (the Student t-test was used for statistical 
evaluation). (B, C) Immunohistochemistry (IHC) staining analysis of Zyxin on colon cancer 
tissue microarrays (p<0.001, Wilcoxon rank sum test). Representative staining images 
were shown (C). -: negative; +: low expression; ++: moderate expression; +++: strong 
expression. (D) Validation of the Zyxin antibody in IHC specificity using control and Zyxin-
knockdown tumors. (E-G) Establishment of colon cancer cell lines with stable knockdown 
of Zyxin. (H-J) Cell migration (wound healing) assays of cell lines established in (E-G). (K, 
L) Anchorage-independent growth (colony assays on soft agar) of HCT116 and SW480 
cell lines with knockdown of Zyxin (F, G). (M-O) Cell proliferation assays in cell lines 
established in (E-G). Data were expressed as the mean ± s.e.m. of three independent 
experiments (H-O). ***: p< 0.001; **: p< 0.01(t-test). 
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Figure 1-7. Zyxin levels are increased in colon cancer patients and knockdown of 
Zyxin inhibits colon cancer cell growth 
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Figure 1-8. Zyxin knockdown impairs migration and anchorage-independent growth 
in colon cancer cells  
(A-C) Representative images for would healing (migration) assays in RKO, SW480, and 
HCT116 cells. (D, E) Representative images for anchorage-independent growth (colony 
assay in soft agar) SW480 and HCT116 cells. (F) Zyxin expression in xenograft tumors. 
Total protein lysates from three tumors of each line were probed with anti-Zyxin and β-
actin antibodies. 
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Figure 1-8. Zyxin knockdown impairs migration and anchorage-independent growth 
in colon cancer cells  
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Figure 1-9. Mitotic phosphorylation of Zyxin is required for colon cancer 
tumorigenesis  
(A) Establishment of Zyxin-knockdown cell lines expressing shRNA-resistant (Res) Zyxin 
or Zyxin-3A in RKO colon cancer cells. 3A: S281A/S308A/S344A. (B, C) Cell migration 
(wound healing) and proliferation assays in cell lines established in (A). (D) Establishment 
of Zyxin-knockdown cell lines expressing shRNA-resistant (Res) Zyxin or Zyxin-3A in 
SW480 colon cancer cells. 3A: S281A/S308A/S344A. (E, F) Cell migration (wound 
healing) and proliferation assays in cell lines established in (D). Data were expressed as 
the mean ± s.e.m. of three independent experiments (B, C, E, and F). ***: p< 0.001; **: p< 
0.01 (Res-Zyxin-WT vs Res-Zyxin-3A) (t-test). (G, H) Zyxin-3A failed to rescue tumor 
growth in Zyxin-knockdown RKO cells. RKO cell lines from (A) were subcutaneously 
inoculated into athymic nude mice (both left and right sides) and the representative tumors 
in each group were excised and photographed at the endpoint (H). Yellow asterisks mark 
the comparisons between Res-Zyxin-WT and Res-Zyxin-3A. ***: p< 0.001; **: p< 0.01 (t-
test). 
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Figure 1-9. Mitotic phosphorylation of Zyxin is required for colon cancer 
tumorigenesis  
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Figure 1-10. Zyxin regulates F-actin polymerization and YAP activity  
(A) Zyxin knockdown increased p-YAP S127 in HCT116 and RKO colon cancer cells. (B) 
Zyxin knockdown impaired YAP nuclear localization in SW480 cells. YAP subcellular 
localization was determined by immunofluorescence confocal microscopy using anti-YAP 
antibodies. (C) Zyxin knockdown inhibited CTGF (YAP target gene) expression. CTGF 
mRNA levels were determined by quantitative RT-PCR. (D) Zyxin regulates cofilin. Cofilin 
activity was analyzed by phospho-specific antibodies. (E) Zyxin knockdown reduced F-
actin polymerization (SW480). F-actin activity was determined by immunofluorescence 
confocal microscopy using anti-F-actin antibodies (Rhodamine Phalloidin, Cytoskeleton). 
(F, G) Establishment of cell lines expressing YAP-S127A in Zyxin-knockdown SW480 and 
HCT116 cells. (H-K) The effects (impaired migration and proliferation) of Zyxin-knockdown 
were rescued by re-expression of YAP-S127A in SW480 and HCT116 cells. Cell 
proliferation (H, J) migration (I, K) and assays using cell lines from (F, G). Data (C, H-K) 
are from three biological repeats and expressed as the mean ± s.e.m. ***: p<0.001; **: 
p<0.01 (t-test). N.S.: not significant. 
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Figure 1-10. Zyxin regulates F-actin polymerization and YAP activity  
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Figure 1-11. Zyxin regulates migration and proliferation through CDK8 in colon 
cancer cells  
(A) Expression profiling of cell cycle regulators identified multiple genes including CDK8 
that are regulated by Zyxin. The RT2 cell cycle arrays (Qiagen) were used and 
experiments were performed following manufacturer’s instructions. F.C.: fold change. (B) 
CDK8 protein levels were decreased in Zyxin-knockdown cells. (C) Establishment of 
Zyxin-knockdown cells expressing Flag-tagged CDK8 or CDK8-KD (kinase dead, D173A). 
(D-F) Migration (wound healing) and proliferation assays in cell lines from (C). Ectopic 
expression of CDK8, but not CDK8-KD, rescued growth defects of Zyxin-knockdown cells. 
(G-I) Transient knockdown (two independent siRNAs) of CDK8 inhibited SW480 cell 
migration (wound healing) and proliferation. (J) Establishment of CDK8 knockout (KO) cell 
lines. Two independent gRNAs were used. (K, L) Cell migration (wound healing) assays 
and proliferation curves of cell lines from (J). (M, N) CDK8 knockout inhibited proliferation 
in DLD-1 cells. Data were expressed as the mean ± s.e.m. of three independent 
experiments (D-F, H, I, K, L, and N). ***: p< 0.001; **: p< 0.01(t-test). 
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Figure 1-11. Zyxin regulates migration and proliferation through CDK8 in colon 
cancer cells  
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Figure 1-12. Zyxin regulates CDK8 expression in colon cancer cells  
(A) Zyxin knockdown inhibited the expression of multiple cell cycle regulators. Candidates’ 
mRNA levels were determined by quantitative RT-PCR. Zyxin serves as a positive control. 
Data are from three biological repeats and expressed as the mean ± s.e.m. ***: p<0.001; 
**: p<0.01 (t-test). (B) Re-introduction of wild type (WT) or the non-phosphorylatable (3A) 
Zyxin rescued CDK8 protein levels in Zyxin-knockdown cells. The CDK8 levels were 
determined by immunoblotting in various cell lines as indicated. (C) CDK8 mRNA levels 
were increased in colon cancer patients (data were extracted from TCGA, the Student t-
test was used for statistical evaluation). (D) CDK8 protein levels were increased in colon 
cancer patients, as revealed by IHC staining on TMAs (N=31 for normal and N=74 for 
tumor/cancer). ***: p<0.001 (Wilcoxon rank sum test). (E) Zyxin and CDK8 protein levels 
are positively correlated in metastatic colon cancer samples. Immunohistochemistry (IHC) 
staining analysis of Zyxin and CDK8 on colon cancer tissue microarrays. +: low 
expression; ++: moderate expression; +++: strong expression. (F) Correlation analysis 
between CDK8 and Zyxin. 
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Figure 1-12. Zyxin regulates CDK8 expression in colon cancer cells  
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Figure 1-13. CDK8 phosphorylates YAP and promotes its activation 
(A, B) Zyxin regulates YAP activity through CDK8. Ectopic expression of CDK8 inhibited 
p-YAP S127 (A) and rescued CTGF (YAP target gene) expression (B) in Zyxin-knockdown 
cells. (C, D) CDK8 regulates YAP activity. CDK8 knockout (KO) increased YAP 
phosphorylation (S127) (C) and inhibited CTGF expression (D). (E-H) YAP is required for 
CDK8-driven proliferation in colon cancer cells. (E, G) Establishment of YAP knockout 
(KO) cell lines. CRISPR/double nickase-mediated (two independent gRNAs were used) 
knockout of YAP in RKO and SW480 cells where Zyxin was depleted and CDK8 re-
expressed. (F, H) Cell proliferation assays for cell lines from (E, G). (I) In vitro kinase 
assays using GST-YAP as substrates. Two batches of CDK8 kinases (SignalChem) were 
used. (J) In vitro kinase assays with His-YAP-WT and -YAP-4A 
(T119A/S128A/S289A/S367A) proteins as substrates. (K) CDK8 phosphorylates YAP in 
mitosis. SW480 control and CDK8-KO cells were treated with DMSO or nocodazole for 
16h. Endogenous YAP proteins were immunoprecipitated and probed with phospho-
antibodies against YAP T119, S128, S289 and total YAP antibodies. Relative 
phosphorylation (fold changes in signal intensity) was quantified by Image J and shown 
below the blots from three independent experiments. SE: short exposure; LE: long 
exposure. (L) CDK8-mediated phosphorylation stimulates YAP transcriptional activity. 
Luciferase reporter assays were done as we described [20]. Data were expressed as the 
mean ± s.e.m. of three biological repeats (B, D, F, H, and L). ***: p< 0.001; **: p< 0.01 (t-
test). 
 
  
49 
 
 
Figure 1-13. CDK8 phosphorylates YAP and promotes its activation 
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Figure 1-14. Detection of autophosphorylation of CDK8 
In vitro kinase assays in the presence (lanes 1 and 2) or absence of His-YAP substrates 
(the 3rd lane). 
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Figure 1-15. YAP phosphorylation is required for CDK8-driven tumorigenesis in 
colon cancer cells 
(A, B) YAP-S127A or β-catenin-S33Y was not sufficient to rescue the proliferation defects 
of CDK8-KO in colon cancer cells. YAP-S127A and β-catenin-S33Y are mutants that are 
the active forms of their corresponding proteins. (C) Establishment of cell lines expressing 
various YAP mutants and/or β-catenin in CDK8 knockout DLD-1 cells. (D) Proliferation 
assays of cell lines expressing various YAP and/or β-catenin mutants as indicated. (E) 
Representative images of anchorage-independent growth (colony assays in soft agar) in 
cell lines as indicated. Data (A, B, and D) are from three biological repeats and expressed 
as the mean ± s.e.m. ***: p<0.001(t-test). 
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Figure 1-15. YAP phosphorylation is required for CDK8-driven tumorigenesis in 
colon cancer cells 
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Figure 1-16. YAP phosphorylation is required for CDK8-driven tumorigenesis in 
colon cancer cells 
(A) Establishment of cell lines expressing various YAP mutants and/or β-catenin in CDK8 
knockout SW480 cells. CA: constitutive active form (S33Y mutant). (B-D) Functional 
assays of cell lines established in (A). Cell migration (wound healing) assays in various 
cell lines as indicated (B). Cell proliferation curves of cell lines with various gene 
expression status (C). Anchorage-independent growth (colony assays in soft agar) in cell 
lines as indicated (D). Data (B-D) are from 3-4 independent experiments and expressed 
as the mean ± s.e.m. ***: p<0.001; **: p<0.01; *: p<0.05 (t-test). (E) Anchorage-
independent growth in various DLD-1 cells lines as indicated. Data are from three 
independent experiments and expressed as the mean ± s.e.m. ***: p<0.001. n.s.: not 
significant. (F, G)  Tumor growth curves and images of all tumors (at the endpoint) from 
SW480 cell lines. 2.5x106 cells (1:1 mixed with Matrigel) were subcutaneously inoculated 
into athymic nude mice on both flanks. N=5 mice and 10 injections/group. Only three 
tumors were formed at the last two time points in the CDK8-KO group and the other three 
groups formed 7-8 tumors (G). Red asterisks mark the comparisons between control and 
CDK8-KO-2; Blue asterisks mark the comparisons between YAP-S127A/4D and CDK8-
KO-2. **: p<0.01; *: p<0.05 (t-test). (H, I) Tumor growth curves and representative images 
of tumors from DLD-1 cell lines. 1.0x106 cells (1:1 mixed with Matrigel) were 
subcutaneously inoculated into athymic nude mice on both flanks (5 mice and 10 
injections/group, 10 tumors were averaged for each group at each time 
point). Red asterisks mark the comparisons between control and CDK8-KO-2; Blue 
asterisks mark the comparisons between YAP-S127A/4D and CDK8-KO-2. ***: p<0.001; 
**: p<0.01; *: p<0.05 (t-test). n.s.: not significant. 
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Figure 1-16. YAP phosphorylation is required for CDK8-driven tumorigenesis in 
colon cancer cells 
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Figure 1-17. CDK8 regulates β-catenin activity in colon cancer cells 
(A, B) CDK8 knockout inhibited β-catenin activity. The β-catenin activity was determined 
by immunoblotting using the inhibitory phospho-antibody (p-S33 β-catenin) (A). LEF1 
mRNA levels (determined by quantitative RT-PCR) were inhibited in CDK8-knockout cells 
(B). Data were expressed as the mean ± s.e.m. of three independent experiments. ***: p< 
0.001(t-test). (C-E) β-catenin knockout inhibited migration and proliferation in colon cancer 
cells. (C) Establishment of β-catenin knockout (KO) cell lines. CRISPR-double nickase-
mediated (two independent gRNAs were used) knockout of β-catenin in RKO cells where 
Zyxin was depleted and CDK8 was re-expressed. Cell migration (wound healing) (D) and 
proliferation (E) assays in cell lines from (C).  Data were expressed as the mean ± s.e.m. 
of three independent experiments. ***: p< 0.001(t-test). 
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Figure 1-17. CDK8 regulates β-catenin activity in colon cancer cells 
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CHAPTER 2: LIMD1 PHOSPHORYLATION IN MITOSIS IS REQUIRED 
FOR MITOTIC PROGRESSION AND ITS TUMOR-
SUPPRESSING ACTIVITY * 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*The material presented in this chapter was previously published: Zhou et al.  FEBS J. 2019 Mar; 
286 (5): 963-974. 
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ABSTRACT 
LIM domains containing 1 (LIMD1) is a member of the Zyxin family of proteins and 
functions as a tumor suppressor in lung cancer. LIMD1 has been shown to regulate Hippo-
YAP signaling activity. Here, we report a novel mechanism for phospho-regulation of 
LIMD1 in mitosis and its biological effects in cancer cell growth. We found that cyclin-
dependent kinase 1 (CDK1) and c-Jun NH2-terminal kinases 1/2 (JNK1/2) phosphorylate 
LIMD1 in vitro and in cells during drug-induced mitotic arrest. Phosphorylation also occurs 
during normal mitosis. S272, S277, S421, and S424 were identified as the main 
phosphorylation sites. Deletion of LIMD1 resulted in a shortened mitotic cell cycle and 
phosphorylation of LIMD1 is required for proper mitotic progression. We further showed 
that the phosphorylation-deficient mutant LIMD1-4A is less active in suppressing cell 
proliferation, anchorage-independent growth, cell migration, and invasion in lung cancer 
cells. Together, our findings reveal a novel layer of regulation for LIMD1 in mitosis and its 
role in tumorigenesis. 
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2.1. Introduction 
Zyxin family members are adaptor/scaffold proteins with three LIM domains, which are 
involved in protein–protein interactions during cellular signaling transduction. In addition 
to Zyxin, this family also includes Ajuba, LIM domains containing 1 (LIMD1), thyroid 
receptor-interacting protein 6 (TRIP6), lipoma-preferred partner (LPP), and Wilms tumor 
1 interacting protein (WTIP). The Zyxin family plays significant roles in many cellular 
processes including cell–cell adhesion, gene transcription, cell growth, and cell cycle 
regulation [63]. 
The LIMD1 locus 3p21.3 is frequently downregulated in human lung tumors and loss 
of LIMD1 expression is mediated through a combination of gene deletion, loss of 
heterozygosity, and promoter methylation [64]. These studies suggest an abrogation of a 
tumor-suppressing role of LIMD1 in lung cancer, which was further supported by in vitro 
and genetic animal models [64, 65]. LIMD1 interacts with pRb and inhibits E2F-mediated 
transcription of targets [65]. Recently, LIMD1 was shown to regulate miRNA-mediated 
silencing through coordinating the assembly of an Argonaute-trinucleotide repeat 
containing 6 (TNRC6)-containing miRNA-induced silencing complex (miRISC) [66]. 
Interestingly, some Zyxin family proteins, including LIMD1, Ajuba, and WTIP, represent a 
previously unrecognized group of hypoxic regulators [67]. For example, LIMD1 acts as a 
molecular scaffold and assembles a prolyl hydroxylase domain (PHD)–LIMD1–von 
Hippel–Lindau (VHL) protein complex that enables efficient degradation of hypoxia-
induced factor-1α (HIF-1α) [67]. Furthermore, LIMD1 itself is a HIF-1 target gene, which 
mediates a negative regulatory feedback mechanism for hypoxic HIF-α degradation in 
tumor growth by modulating PHD2–LIMD1–VHL complex formation [68]. Several reports 
suggest that LIMD1 controls tissue and cell growth through Hippo-YAP/Yki signaling [63, 
69-71], which plays critical roles in development and tumorigenesis [12, 13, 72, 73]. 
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Mitotic aberration can cause aneuploidy or genomic instability, which is highly 
associated with human malignancy [74, 75]. Interestingly, several earlier studies have 
shown that some Zyxin family members (e.g., Zyxin, Ajuba, and LIMD1) are 
phosphorylated in mitosis and interact with the mitotic machinery [22, 76, 77]. LIMD1 is a 
novel BRCA2-interacting protein and is required for the centrosome localization of BRCA2 
[78]. These studies suggest that Zyxin family proteins function as tumor suppressors or 
tumor promoters through, at least in part, dysregulation of mitosis. We recently 
characterized the phospho-regulation of Ajuba and Zyxin and determined their roles in 
mitosis and tumorigenesis [30, 79]. Phosphorylation sites, corresponding kinases, and 
their functional significance for LIMD1 in mitosis remain elusive, however. 
In this report, we showed that LIMD1 is phosphorylated in mitosis. We identified cyclin-
dependent kinase 1 (CDK1) and c-Jun NH2-terminal kinases 1/2 (JNK1/2) as the 
upstream kinases for LIMD1 phosphorylation. We further demonstrated that LIMD1 
phosphorylation controls proper completion of mitotic progression and is required for 
LIMD1 tumor-suppressing activity. 
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2.2. Materials and Methods 
2.2.1    Expression constructs, cell culture and transfection 
His-LIMD1, His-LIMD1-4A (S272A/S277A/S421A/S424A), and V5-LIMD1 have been 
described [70]. To make the lentiviral LIMD1 expression constructs, the full-length LIMD1 
cDNA (wild type or 4A) was cloned into the pSIN4-Flag-IRES-puro vector [25]. The 
lentiviral-mRFP-H2B (18982) [80] and GFP-Cyclin B1-R42A (61849) [81] constructs were 
purchased from Addgene. HEK293T, HEK293GP, U2OS, HeLa, HCT116, and Panc-1 cell 
lines were purchased from American Type Culture Collection (ATCC) and cultured as 
ATCC instructed. The HPNE cell line was provided by Dr. Michel Ouellette (University of 
Nebraska Medical Center), who originally established the cell line [82]. The human lung 
cancer cell lines, A549 and H520, were obtained from the Cell Bank of the Chinese 
Academy of Sciences (Shanghai, China). Both cell lines were maintained in RPMI-1640 
medium with 10% fetal bovine serum and 1% penicillin/streptomycin (Invitrogen). All cells 
were cultured in incubators with 95% air and 5% CO2 at 37 °C. 
Attractene (Qiagen) was used for transient overexpression of proteins in HEK293T 
and HEK293GP cells following the manufacturer’s instructions. Nocodazole (100 ng/ml for 
16 h) and taxol (100 nM for 16 h) (Selleck Chemicals) were used to arrest cells in G2/M 
phase. VX680 (Aurora-A, -B, -C inhibitor), MK5108 (Aurora-A inhibitor), BI2536 (PLK1 
inhibitor), Purvalanol A (CDK1/2/5 inhibitor), SP600125 (JNK1/2 inhibitor) and MK2206 
(Akt inhibitor) were also from Selleck Chemicals. RO3306 (CDK1 inhibitor) was from 
ENZO Life Sciences. Kinase inhibitors for MEK-ERK (U0126), p38 (SB203580), and 
mTOR (Rapamycin) were from LC Laboratory. All other chemicals were either from Sigma 
or from Thermo Fisher.  
2.2.2   Recombinant protein purification and in vitro kinase assay 
62 
GST-tagged LIMD1 or LIMD1-4A (S272A/S277A/S421A/S424A; cloned in pGEX-5X-
1) was bacterially expressed and purified on GSTrap FF affinity columns (GE Healthcare) 
following the manufacturer’s instructions. GST-LIMD1/LIMD1-4A (0.25 µg) was incubated 
with 5-10 U recombinant CDK1/cyclin B complex (New England Biolabs) or 50-100 ng 
CDK1/cyclin B (SignalChem) in kinase buffer (New England Biolabs) in the presence of 
10 µCi γ-32P-ATP (3000 Ci/mmol, PerkinElmer) as we previously described [21]. Active 
CDK2, CDK5, p38α, JNK1, JNK2, MEK1, ERK1, and ERK2 kinases were also purchased 
from SignalChem. 
2.2.3   Antibodies 
Rabbit polyclonal phospho-specific antibodies against human LIMD1 S272, S277, and 
S421/S424 were generated and purified by AbMart Inc. The peptides used for immunizing 
rabbits were: SSQRV-pS-PGLPSP (p-S272); SPGLP-pS-PNLEN (p-S277); SVLLD-pS-
PS-pS-PRVRLP (p-S421/424). The corresponding non-phosphorylated peptide was also 
synthesized and used for antibody purification. Anti-β-actin (SC-47778) and anti-cyclin B 
(SC-752) antibodies were from Santa Cruz Biotechnology. Glutathione S-transferase 
(GST) (A190-122A) and His (A190-114A) antibodies were from Bethyl Laboratories. 
Phospho-S10 H3 (3377), phospho-S127 YAP (13008), phospho-S397 YAP (13619), YAP 
(12395), LIMD1 (13245), phospho-Aurora-A (T288)/Aurora-B (T232)/Aurora-C (T198) 
(2914), and Aurora-A (14475) antibodies were from Cell Signaling Technology. 
2.2.4   Phos-tag and Western blot analysis 
Phos-tagTM was obtained from Wako Pure Chemical Industries, Ltd. and used at 10-
20 µM (with 100 µM MnCl2) in 8% SDS-polyacrylamide gels as we previously described 
[30]. Western blotting, immunoprecipitation, and lambda phosphatase treatment assays 
were done as previously described [23, 27]. 
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2.2.5   Cell proliferation and colony formation assays 
The LIMD1-wild type or LIMD1-4A plasmid was transfected to A549 and H520 cell 
lines by transfection reagent Lipo2000 (Invitrogen) according to the manufacturer’s 
protocol. For cell proliferation assays, 10,000 cells were seeded into each well of 24-well 
plates in triplicate and proliferation curves were made from three independent experiments 
[79]. Colony formation assays in soft agar were performed as described [20]. Cells were 
seeded into 6-well plates in triplicate (2,000 cells/well) for 14 days. 
2.2.6   Migration and invasion assays 
Migration (wound healing) and invasion (Transwell plates with Matrigel, BD 
Biosciences) assays were done as described [83]. 
2.2.7   CRISPR-Cas9-mediated LIMD1 deletion 
The CRISPR-LIMD1 and double nickase constructs were purchased from Santa Cruz 
Biotechnology (SC-404413-NIC). The plasmids were transiently transfected into cells and 
GFP-positive clones were selected by flow cytometry-based cell sorting [79]. 
2.2.8   Live-cell imaging microscopy 
RFP-H2B-transduced U2OS cells were cultured in FluroBrite DMEM (Thermo Fisher) 
on black 96-well optical bottom plates (Thermo Fisher). Cells were monitored for 24 h and 
pictures taken every 5 min using an RFP filter on a Cellomics Arrayscan VTI HCS Reader. 
2.2.9   Immunofluorescence staining and confocal microscopy 
Immunofluorescence staining and microscopy were done as previously described [28]. 
2.2.10 Statistical analysis 
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Statistical significance was analyzed using a two-tailed, unpaired Student’s t-test. The 
Mann Whitney test was used for comparing the mitotic length (Fig. 2-5). A p-value <0.05 
was considered as statistically significant. 
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2.3. Results and Discussion 
2.3.1    LIMD1 is phosphorylated during anti-tubulin drug-induced mitotic arrest 
We recently found that many Hippo pathway proteins are phosphorylated in response 
to anti-tubulin drug (taxol or nocodazole)-induced mitotic arrest [30]. These studies 
revealed that LIMD1 was dramatically upshifted on a Phos-tag SDS/PAGE during mitotic 
arrest in HeLa cervical cancer cells (Fig. 2-1A) [30]. The mobility shift was also evident in 
HPNE (an immortalized but not transformed human pancreatic nestin-expressing cell line) 
and other cancer cell lines (HCT116 colon cancer cells and Panc-1 pancreatic cancer 
cells) (Fig. 2-1B). Lambda phosphatase treatment completely abolished the mobility 
upshift of LIMD1, confirming that the mobility upshift of LIMD1 is due to phosphorylation 
during mitotic arrest (Fig. 2-1C). 
2.3.2    Identification of the upstream kinase(s) for LIMD1 phosphorylation 
In order to identify the corresponding kinase(s) for LIMD1 phosphorylation, we treated 
the cells with various kinase inhibitors. Treatment with SB203580 (p38 inhibitor), U0126 
(MEK-ERK inhibitor), MK2206 (Akt inhibitor), BI2536 (PLK1 inhibitor), VX680 (Aurora-A, -
B, -C inhibitor), MK5108 (Aurora-A inhibitor), or rapamycin (mTOR inhibitor), which were 
effective under the conditions [21, 84], failed to alter the mobility/phosphorylation of LIMD1 
during mitotic arrest (Fig. 2-1D). Interestingly, LIMD1 mobility shift was reverted by the 
addition of RO3306 (CDK1 inhibitor) or purvalanol A (CDK1/2/5 inhibitor) (Fig. 2-1D, lanes 
5, 6). The inhibition of JNK1/2 (with SP600125) partially blocked the mobility shift of LIMD1 
(Fig. 2-1D). These data suggest that CDK1 and JNK1/2 are the potential upstream kinases 
for LIMD1 phosphorylation during taxol- or nocodazole-induced mitotic arrest. 
2.3.3    CDK1 and JNK1/2 phosphorylate LIMD1 in vitro 
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To determine whether CDK1 and JNK1/2 can directly phosphorylate LIMD1, we 
performed in vitro kinase assays with purified recombinant LIMD1 proteins as substrates. 
In the presence of purified CDK1/cyclin B kinase complex, 32P-labeled c-ATP was robustly 
incorporated in GST-LIMD1 proteins (Fig. 2-2A). Consistent with a previous study [70], 
JNK1/2 kinases, to a lesser extent when compared with CDK1 kinase, also 
phosphorylated LIMD1 (Fig. 2-2A). We also included some other similar kinases including 
CDK2, CDK5, MEK1, ERK1, ERK2, or p38α in these assays and showed that none of 
them could phosphorylate LIMD1 (Fig. 2-2A). These results suggest that LIMD1 is a 
suitable substrate for CDK1 and JNK1/2 in vitro. 
2.3.4    LIMD1 S272, S277, S421, and S424 are the main sites phosphorylated by 
CDK1 and JNK1/2 in vitro 
CDK1 and JNK1/2 kinases phosphorylate a minimal S/TP consensus sequence [33]. 
Database analysis (www.phosphosite.org) revealed four sites (S272, S277, S421, and 
S424) that have been identified as potential mitotic phosphorylation sites through 
largescale proteomic studies [34, 85]. All these four sites fit the CDK1 and JNK1/2 
phospho-consensus sequence and have been identified as JNK1/2 phosphorylation sites 
[70]. We tested the possibility that these sites are phosphorylated by CDK1. In the 
presence of CDK1 kinase, the 32P incorporation in GST-LIMD1-4A 
(S272A/S277A/S421A/S424A) was largely eliminated, suggesting that S272, S277, S421, 
and S424 are the main CDK1 sites in LIMD1 in vitro (Fig. 2-2B). Similar observations were 
obtained when JNK1/2 kinases were used (Fig. 2-2C). We have generated phospho-
specific antibodies against S272, S277, and S421/S424. In vitro kinase assays confirmed 
that JNK1/2 kinases could phosphorylate LIMD1 at S272, S277, and S421/S424 (Fig. 2-
2D). CDK1 also phosphorylated LIMD1 at S421/S424, but could not phosphorylate S272 
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and S277 of LIMD1 under these conditions (Fig. 2-2D). These data indicate that CDK1 
and JNK1/2 phosphorylate LIMD1 at S272, S277, and S421/S424 in vitro. 
2.3.5    CDK1 and JNK1/2 phosphorylate LIMD1 at S272 and S277 in cells 
We further explored whether LIMD1 is phosphorylated within cells during 
taxol/nocodazole-induced mitosis. The phospho-signals of S272 and S277 of transfected 
LIMD1 were significantly increased after taxol or nocodazole treatment (Fig. 2-3A). 
Mutating serines to alanines abolished the phosphorylation signal, suggesting that these 
antibodies specifically recognize phosphorylated LIMD1 (Fig. 2-3A). The addition of 
RO3306 (CDK1 inhibitor) or SP600125 (JNK1/2 inhibitor) greatly inhibited LIMD1 S272 
and S277 phosphorylation (Fig. 2-3B). Taxol treatment also increased phosphorylation at 
S272 and S277 of endogenous LIMD1 in a CDK1- and JNK1/2-dependent manner (Fig. 
2-3C). Lambda phosphatase treatment eliminated the phospho-signal induced by taxol, 
further confirming the specificity of these antibodies (Fig. 2-3D). We could not detect a 
specific signal when the phospho-S421/S424 antibody was used in these experiments. 
Since inhibition of either CDK1 or JNK1/2 eliminates most phosphorylation (Fig. 2-3B 
and C), it implies that they should not both be directly phosphorylating LIMD1 on these 
sites in cells and that SP600125 or RO3306 has an indirect effect on the other kinase. 
Overexpression of nondegradable (constitutive active) GFP-Cyclin B1-R42A (activator of 
CDK1 kinase) increased p-LIMD1 S272 and S277 (Fig. 2-4A). Moreover, inducible 
knockdown of CDK1 significantly reduced p-LIMD1 S272 and S277 levels induced by taxol 
treatment (Fig. 2-4B). These observations suggest that CDK1 mediates LIMD1 
phosphorylation. However, it is still unclear whether this phosphorylation occurs through 
a direct or indirect mechanism. 
We next asked whether phosphorylation of LIMD1 occurs during normal mitosis. First, 
we examined the phospho-status of LIMD1 using a double thymidine block and release 
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method [27]. We showed that the phospho-LIMD1 signal (at S272 and S277) was 
significantly increased in cells entering mitosis (10 h post-double thymidine block and 
release) (Fig. 2-4C). The phospho-level of LIMD1 decreased when cells exited from 
mitosis (24 h after release) (Fig. 2-4C). Second, we performed immunofluorescence 
staining with our phospho-specific antibodies in freely cycling cells. We found that LIMD1 
phosphorylation at S277 and S421/S424 significantly increased when cells progressed 
into mitosis. The highest phosphorylation levels were detected in metaphase cells (Fig. 2-
4D and E). The p-LIMD1 signal was almost undetectable in interphase cells. The staining 
signals were abolished in LIMD1-knockout (KO) cells, confirming the specificity of p-
LIMD1 antibodies (Fig. 2-4D and E, bottom lows). Furthermore, treatment with RO3306 or 
Purvalanol A largely abolished the phospho-signal (Fig. 2-4D and E). Together, these 
observations indicate that LIMD1 phosphorylation occurs during normal mitosis likely in a 
CDK1-dependent manner. 
2.3.6   Mitotic phosphorylation of LIMD1 affects mitotic progression 
Next, we asked whether LIMD1 plays a role in mitotic progression. For this purpose, 
we deleted LIMD1 in U2OS osteosarcoma cells using a CRISPR-Cas9 approach. These 
cell lines were further transduced with RFP-H2B for live-cell imaging microscopy. We 
found that LIMD1 deletion shortened the duration of early mitotic phases [from nuclear 
envelope breakdown (NEBD) to anaphase onset] (Fig. 2-5A and B). Adding back of wild-
type LIMD1 largely restored the mitotic defects induced upon LIMD1 deletion (Fig. 2-5C). 
However, reexpression of the LIMD1-4A mutant failed to do so, suggesting that mitotic 
phosphorylation is required for proper mitotic progression (Fig. 2-5C). The LIMD1 is a 
regulator of the Hippo-YAP signaling [69-71]. We thus tested whether LIMD1 
phosphorylation affects YAP activity. S127 is a major phosphorylation site mediated by 
LATS1/2 kinases [20, 86], and S397 phosphorylation promotes YAP degradation [87]. In 
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HeLa and U2OS cells, the S127 and S397 phosphorylation levels of YAP were not altered 
in LIMD1-KO cells when compared with control cells (Fig. 2-5D). Transfection of LIMD1-
WT or LIMD1-4A into LIMD1-KO cells did not affect YAP activity either, as shown by the 
lack of changes in phosphorylation (Fig. 2-5D). These observations suggest that unlike 
Zyxin [79], inactivation of LIMD1 does not significantly affect YAP phosphorylation, at least 
in the cells tested. 
2.3.7   Mitotic phosphorylation of LIMD1 is required for its inhibitory activity in cell 
proliferation and anchorage-independent growth 
The LIMD1 is a tumor suppressor in lung cancer [64]. We next asked whether mitotic 
phosphorylation of LIMD1 plays a role in regulating its tumor-suppressing activity in lung 
cancer cells. We compared the effects from empty vector-, LIMD1-WT-, or LIMD1- 4A-
transfected lung cancer cells (Fig. 2-6A). As expected, enhanced expression of LIMD1-
WT significantly inhibited proliferation and anchorage-independent growth in A549 lung 
cancer cells (Fig. 2-6B–D). Interestingly, overexpression of the LIMD1-4A mutant only 
partially reduced cell proliferation and colony formation when compared to LIMD1-WT-
expressing cells (Fig. 2-6B–D). Similar results were obtained in H520 lung cancer cells 
(Fig. 2-6E–H). These data suggest that mitotic phosphorylation is indispensable for LIMD1 
activity in suppressing cell proliferation and anchorage-independent growth. 
2.3.8   Mitotic phosphorylation of LIMD1 is required for its inhibitory activity in cell 
migration and invasion 
We further interrogated the biological significance of mitotic phosphorylation of LIMD1 
on cell migration and invasion. Consistent with the observations in cell proliferation and 
anchorage-independent growth (Fig. 2-6), overexpression of LIMD1-WT greatly inhibited 
migration, as shown by the wound healing assay (Fig. 2-7A) and invasion (Fig. 2-7B and 
C) in H520 cells. Again, ectopic expression of LIMD1-4A suppressed migration and 
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invasion to a significantly lesser extent when compared with LIMD1-WT transfected cells 
(Fig. 2-7A–C). Similar results were obtained in A549 cells (Fig. 2-7D and E). These results 
suggest that phosphorylation of LIMD1 enhances its tumor-suppressing activity in 
migration and invasion in lung cancer cells. 
Taken together, our data show that the Zyxin family protein LIMD1, in addition to Zyxin 
itself and Ajuba [30, 79], is phosphorylated in mitosis. Mitotic phosphorylation of LIMD1 
regulates mitotic progression and is required for its tumor-suppressing activity in lung 
cancer cells. Future studies are needed to determine whether these three members have 
compensatory effects during the mitotic cell cycle. Our findings showed that LIMD1 and 
its mitotic phosphorylation did not affect the YAP activity in U2OS and HeLa cancer cells, 
and thus, it will be interesting to unveil the downstream signaling and effector of LIMD1 in 
mitosis and tumor-suppressing activity.  
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Figure 2-1. CDK1- and JNK1/2-dependent phosphorylation of LIMD1 during anti-
tubulin drug-induced mitotic arrest 
(A) HeLa cells were treated with DMSO, taxol or nocodazole. Total cell lysates were 
probed with the indicated antibodies on Phos-tag or regular SDS-polyacrylamide gels. 
Increased levels of cyclin B1 mark cells in mitosis. (B) HPNE, HCT116, and Panc-1 cells 
were treated with DMSO or nocodazole. Total cell lysates were probed with the indicated 
antibodies on Phos-tag or regular SDS-polyacrylamide gels. Elevated levels of p-Aurora 
kinases indicate cells in mitosis. (C) HeLa cells were treated with nocodazole as indicated 
and cell lysates were further treated with (+) or without (-) λ phosphatase (ppase). Total 
cell lysates were probed with anti-LIMD1 antibody on Phos-tag or regular SDS-
polyacrylamide gels. (D) HeLa cells were treated with nocodazole together with or without 
various kinase inhibitors as indicated. RO3306 (CDK1 inhibitor, 5 µM), Purvalanol A 
(CDK1/2/5 inhibitor, 10 µM), SB203580 (p38 inhibitor, 10 µM), SP600125 (JNK1/2 
inhibitor, 20 µM), U0126 (MEK-ERK inhibitor, 20 µM), MK2206 (AKT inhibitor, 10 µM), 
BI2536 (PLK1 inhibitor, 100 nM), VX680 (Aurora-A, B, C inhibitor, 2 µM), and MK5108 
(Aurora-A inhibitor, 5 µM) were used. Inhibitors were added 1.5 h before harvesting the 
cells (with MG132 to protect cyclin B1 from degradation and prevent cells from exiting 
from mitosis). Total cell lysates were subjected to Western blotting with the indicated 
antibodies. All Western blots are representative of three repeats. 
 
  
72 
 
 
Figure 2-1. CDK1- and JNK1/2-dependent phosphorylation of LIMD1 during anti-
tubulin drug-induced mitotic arrest 
  
73 
Figure 2-2. CDK1 and JNK1/2 phosphorylate LIMD1 in vitro 
(A) In vitro kinase assays with kinases as indicated using GST-LIMD1 proteins as 
substrates. ERK1 kinase was not detectable in this context. (B) In vitro kinase assays with 
CDK1/cyclin B complex using GST-LIMD1 or GST-LIMD1-4A proteins as substrates. 4A: 
S272A/S277A/S421A/S424A. (C) In vitro kinase assays with JNK1/2 kinases using GST-
LIMD1 or GST-LIMD1-4A proteins as substrates. 4A: S272A/S277A/S421A/S424A. (D) In 
vitro kinase assays were done as in A except anti-p-S272, -S277, and -S421/S424 LIMD1 
antibodies were used. All experiments are representative of two biological repeats. 
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Figure 2-3. CDK1 and JNK1/2 mediate the phosphorylation of LIMD1 in cells 
(A) HEK293T cells were transfected with the indicated LIMD1 cDNA and at 48 h post-
transfection, the cells were treated with taxol or nocodazole (noco) for an additional 18 h. 
Total cell lysates were subjected to Western blotting with the indicated antibodies. 
(B) HEK293T cells were transfected with V5-LIMD1 cDNA, and at 36 h post-transfection 
the cells were treated with taxol as indicated for an additional 18 h. CDK1 inhibitor (CDKi, 
RO3306, 5 µM) or JNK1/2 inhibitor (JNKi, SP600125, 20 µM) together with MG132 (25 
µM) were added 1.5 h before the cells were lysed. Total cell lysates were subjected to 
Western blotting with the indicated antibodies. (C) HeLa cells were treated with taxol as 
indicated for 18 h.  CDK1 inhibitor (CDKi, RO3306, 5 µM) or JNK1/2 inhibitor (JNKi, 
SP600125, 20 µM) together with MG132 (25 µM) were added 1.5 h before the cells were 
lysed. LIMD1 proteins were immunoprecipitated and the samples were probed with 
phospho-LIMD1 and subsequent LIMD1 antibodies. (D) HEK293T cells were transfected 
with V5-LIMD1 and treated with taxol as indicated and cell lysates were further treated 
with (+) or without (-) λ phosphatase (ppase). Total cell lysates were probed with the 
indicated antibodies. P-Aurora A/B serves as a positive marker. All experiments are 
representative of three biological repeats. 
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Figure 2-4. Phosphorylation of LIMD1 occurs during normal mitosis in a CDK1-
dependent manner 
(A) HEK293T cells were transfected with the indicated DNA constructs and total cell 
lysates were analyzed by Western blotting. GFP-Cyc B1: GFP-Cyclin B1-R42A (a non-
degradable constitutive active mutant). (B) CDK1 knockdown inhibited LIMD1 
phosphorylation. TetOn-inducible shRNA targeting CDK1 was expressed in HeLa cells. 
The cells were treated with or without Doxycycline (Dox) for 2 days and were further 
treated with taxol for an additional 16 h. Endogenous LIMD1 was immunoprecipitated and 
subjected to Western blotting with the indicated antibodies. Increased p-H3 S10 levels 
mark the cells in mitosis. (C) A double thymidine (DT) block and release was performed 
in HeLa cells and samples were collected at the indicated time points. LIMD1 proteins 
were immunoprecipitated and the samples were probed with the indicated antibodies. 
Phospho-S10 H3 serves as a mitotic marker. (D, E) Immunofluorescence staining of p-
LIMD1 S277 (D) and p-LIMD1 S421 (p-S421/S424, E) in freely cycling HeLa cells. White 
arrows mark cells in metaphase (condensed and aligned chromosomes). CDK1 inhibitors 
(Purvalanol A or RO3306) were added 1.5 h before the cells were fixed. All experiments 
are representative of two biological repeats. 
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Figure 2-5. Mitotic phosphorylation of LIMD1 is required for mitotic progression 
(A, B) Representative live images of control and LIMD1-KO cells. (C) Quantification of 
mitotic length [from NEBD (nuclear envelope breakdown) to anaphase] from control 
(n=80), LIMD1-KO (n=80), LIMD1-KO+LIMD1-WT (n=72), and LIMD1-KO+LIMD1-4A 
(n=72) cells. ***: p<0.001 (Mann Whitney test). (D) Deletion of LIMD1 does not affect YAP 
phosphorylation/activity in HeLa and U2OS cells. The U2OS LIMD1-KO cell line was used 
to establish cell lines expressing vector, LIMD1-WT, or LIMD1-4A. 4A: 
S272A/S277A/S421A/S424A. WT: wild type. Total cell lysates from these cell lines were 
probed with the indicated antibodies. Experiments were done at high cell density (>85% 
confluence). Data in panel D are representative of three biological repeats. 
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Figure 2-6. Mitotic phosphorylation of LIMD1 is required for suppressing 
proliferation and anchorage-independent growth in lung cancer cells 
(A) Western blotting analysis of LIMD1 expression in A549 cells transfected with vector 
(control), LIMD1-WT, or LIMD1-4A DNA. 4A: S272S/S277A/S421A/S424A. (B-D) Cell 
proliferation and anchorage-independent growth (colony formation assays in soft agar) 
assays with A549 cells from A. Data were expressed as the mean ± s.d. of three 
independent repeats. Representative images for colony assay were shown (D). Red 
asterisks mark the comparisons between LIMD1-4A and LIMD1-WT. Blue asterisks mark 
the comparisons between Vector and LIMD1-WT. ***: p<0.001, **: p< 0.01; *: p< 0.05 (t-
test). (E-H) Similar experiments were done as A-D in H520 cells. Data were expressed as 
the mean ± s.d. of three repeats. Representative images for colony assay were shown 
(H). Red asterisks mark the comparisons between LIMD1-4A and LIMD1-WT. Blue 
asterisks mark the comparisons between Vector and LIMD1-WT. ***: p<0.001, **: p< 0.01; 
*: p< 0.05 (t-test). 
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Figure 2-7. Mitotic phosphorylation of LIMD1 is required for suppressing migration 
and invasion in lung cancer cells 
(A) Cell migration (wound healing) assays in H520 cells transfected with vector (control), 
LIMD1-WT, or LIMD1-4A. Representative images were shown. 4A: 
S272S/S277A/S421A/S424A. (B, C) Cell invasion assays of H520 cells transfected with 
vector (control), LIMD1-WT, or LIMD1-4A. Data were expressed as the mean ± s.d. of 
three repeats (C) and representative images were shown (B). ***: p<0.001, *: p< 0.05 (t-
test). (D, E) Cell invasion assays of A549 cells transfected with vector (control), LIMD1-
WT, or LIMD1-4A. Data were expressed as the mean ± s.d. of three repeats (D) and 
representative images were shown (E). ***: p<0.001, **: p< 0.01 (t-test). 
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Figure 2-7. Mitotic phosphorylation of LIMD1 is required for suppressing migration 
and invasion in lung cancer cells 
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